DK3390395T3 - Forbindelser, der kan anvendes som kinase-inhibitorer - Google Patents
Forbindelser, der kan anvendes som kinase-inhibitorer Download PDFInfo
- Publication number
- DK3390395T3 DK3390395T3 DK16816363.2T DK16816363T DK3390395T3 DK 3390395 T3 DK3390395 T3 DK 3390395T3 DK 16816363 T DK16816363 T DK 16816363T DK 3390395 T3 DK3390395 T3 DK 3390395T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 0 CC(C1)OC(C)CC1N(C(*)=C)N=C Chemical compound CC(C1)OC(C)CC1N(C(*)=C)N=C 0.000 description 18
- NSEINQXWHOBDKC-UHFFFAOYSA-N C=C(N(C(CCC1)C1F)N=C)N=N Chemical compound C=C(N(C(CCC1)C1F)N=C)N=N NSEINQXWHOBDKC-UHFFFAOYSA-N 0.000 description 1
- AXDZAXNGDDLYCQ-UHFFFAOYSA-N C=C(N)N(C1COCCC1)N=C Chemical compound C=C(N)N(C1COCCC1)N=C AXDZAXNGDDLYCQ-UHFFFAOYSA-N 0.000 description 1
- VKOTXBDIFYBQOP-UHFFFAOYSA-N COc(c(C(NCc(cc1)cc(F)c1-c1n[n](C2CCOCC2)c(N)c1C(N)=O)=O)c1)ccc1F Chemical compound COc(c(C(NCc(cc1)cc(F)c1-c1n[n](C2CCOCC2)c(N)c1C(N)=O)=O)c1)ccc1F VKOTXBDIFYBQOP-UHFFFAOYSA-N 0.000 description 1
- YHWVHTJPUOHJOC-UHFFFAOYSA-N COc(c(C(NCc(cc1)ccc1-c1n[n](C2COCC2)c(N)c1C(N)=O)=O)c1)ccc1F Chemical compound COc(c(C(NCc(cc1)ccc1-c1n[n](C2COCC2)c(N)c1C(N)=O)=O)c1)ccc1F YHWVHTJPUOHJOC-UHFFFAOYSA-N 0.000 description 1
- ASMXABMECVFUAG-UHFFFAOYSA-N COc(cccc1)c1C(NCc(c(F)c1)ccc1-c1n[n](C2CCOCC2)c(N)c1C(N)=O)=O Chemical compound COc(cccc1)c1C(NCc(c(F)c1)ccc1-c1n[n](C2CCOCC2)c(N)c1C(N)=O)=O ASMXABMECVFUAG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522245.8A GB201522245D0 (en) | 2015-12-16 | 2015-12-16 | Compounds useful as kinase inhibitors |
GBGB1613945.3A GB201613945D0 (en) | 2016-08-15 | 2016-08-15 | Compounds useful as kinase inhibitors |
PCT/GB2016/053968 WO2017103611A1 (en) | 2015-12-16 | 2016-12-16 | Compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3390395T3 true DK3390395T3 (da) | 2020-09-28 |
Family
ID=57590725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16816363.2T DK3390395T3 (da) | 2015-12-16 | 2016-12-16 | Forbindelser, der kan anvendes som kinase-inhibitorer |
Country Status (36)
Country | Link |
---|---|
US (7) | US10695323B2 (da) |
EP (2) | EP3390395B1 (da) |
JP (3) | JP6731483B2 (da) |
KR (2) | KR102215792B1 (da) |
CN (9) | CN114591242A (da) |
AU (4) | AU2016373530B2 (da) |
CA (1) | CA3008488C (da) |
CL (1) | CL2018001591A1 (da) |
CO (1) | CO2018006164A2 (da) |
CR (1) | CR20180367A (da) |
CY (1) | CY1123561T1 (da) |
DK (1) | DK3390395T3 (da) |
EA (1) | EA035132B1 (da) |
ES (1) | ES2828431T3 (da) |
FI (1) | FIC20240004I1 (da) |
FR (1) | FR24C1009I1 (da) |
HK (1) | HK1263254A1 (da) |
HR (1) | HRP20201835T1 (da) |
HU (2) | HUE051921T2 (da) |
IL (4) | IL285976B2 (da) |
LT (1) | LT3390395T (da) |
MA (2) | MA55064A (da) |
MD (1) | MD3390395T2 (da) |
MX (2) | MX2018007267A (da) |
NL (1) | NL301262I2 (da) |
NZ (1) | NZ743553A (da) |
PE (3) | PE20181449A1 (da) |
PH (1) | PH12018501268A1 (da) |
PT (1) | PT3390395T (da) |
RS (1) | RS60982B1 (da) |
SG (2) | SG11201805044WA (da) |
SI (1) | SI3390395T1 (da) |
TN (1) | TN2018000213A1 (da) |
UA (2) | UA127863C2 (da) |
WO (1) | WO2017103611A1 (da) |
ZA (4) | ZA201804137B (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー, インコーポレイテッド | がんの治療のためのbtk阻害剤としてのピラゾロピリミジン誘導体 |
UA127863C2 (uk) | 2015-12-16 | 2024-01-31 | Локсо Онколоджі, Інк. | Сполуки, які можна застосовувати як інгібітори кінази |
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
AU2019247533B2 (en) * | 2018-04-06 | 2023-09-28 | Altos Labs, Inc. | ATF6 inhibitors and uses thereof |
JP6995195B2 (ja) | 2018-05-18 | 2022-02-04 | 富士フイルム株式会社 | 3-ジフルオロメチルピラゾール化合物の製造方法及び3-ジフルオロメチルピラゾール-4-カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物 |
US20210330643A1 (en) * | 2018-07-31 | 2021-10-28 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
WO2021053234A1 (en) * | 2019-09-19 | 2021-03-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Compounds and compositions for treating kidney disease |
CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
JP7142173B2 (ja) | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー, インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
CN115443277A (zh) * | 2020-03-12 | 2022-12-06 | 重庆复尚源创医药技术有限公司 | 作为激酶抑制剂的化合物 |
TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
CN116348453A (zh) * | 2021-04-25 | 2023-06-27 | 烨辉医药科技(上海)有限公司 | 杂芳族甲酰胺化合物及其用途 |
EP4337196A1 (en) | 2021-05-14 | 2024-03-20 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
CN115557933A (zh) * | 2021-07-01 | 2023-01-03 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
WO2023284765A1 (zh) * | 2021-07-16 | 2023-01-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
WO2023143355A1 (en) * | 2022-01-28 | 2023-08-03 | Hansoh Bio Llc | Azacycle amide derivative, preparation methods and medicinal uses thereof |
WO2023174397A1 (en) * | 2022-03-18 | 2023-09-21 | Insilico Medicine Ip Limited | Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof |
CN115894376A (zh) * | 2022-12-15 | 2023-04-04 | 南京雷正医药科技有限公司 | 一种芳香族酰胺类化合物、药物组合物及其用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
CZ2002936A3 (cs) | 1999-09-17 | 2002-10-16 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidiny jako terapeutické prostředky |
US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
WO2008063287A2 (en) * | 2006-10-06 | 2008-05-29 | Abbott Laboratories | Novel imidazothiazoles and imidazoxazoles |
ES2403546T3 (es) | 2006-11-03 | 2013-05-20 | Pharmacyclics, Inc. | Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización |
SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
JP5369183B2 (ja) | 2008-07-16 | 2013-12-18 | ファーマサイクリックス,インク. | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
PT2324008E (pt) * | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
DK2588465T3 (da) * | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | Sgc-stimulatorer |
PL2710007T3 (pl) | 2011-05-17 | 2020-06-01 | The Regents Of The University Of California | Inhibitory kinazy |
EP2710005B1 (en) | 2011-05-17 | 2016-10-05 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス,インク. | Bruton型チロシンキナーゼの阻害剤 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
KR102150432B1 (ko) | 2012-06-18 | 2020-09-01 | 프린시피아 바이오파마, 인코퍼레이티드 | 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘 |
WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
MA37830B1 (fr) * | 2012-08-10 | 2018-09-28 | Boehringer Ingelheim Int | Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) |
GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
MD20150035A2 (ro) * | 2012-11-02 | 2015-10-31 | Pfizer Inc. | Inhibitori de tirozinkinaza Bruton |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
US9951056B2 (en) * | 2013-09-30 | 2018-04-24 | Beijing Innocare Pharma Tech Co., Ltd. | Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
WO2015075051A1 (en) * | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Allosteric inhibitors of atypical protein kinases c |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
MX2017009831A (es) | 2015-01-28 | 2017-11-02 | Bayer Pharma AG | Derivados de 4h-pirrol[3,2-c]piridin-4-ona. |
GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー, インコーポレイテッド | がんの治療のためのbtk阻害剤としてのピラゾロピリミジン誘導体 |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP6856662B2 (ja) | 2015-12-16 | 2021-04-07 | プライオスター プロプライアタリー リミティド | デンドリマー及びその製剤 |
EA034561B1 (ru) | 2015-12-16 | 2020-02-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний |
WO2017106623A1 (en) | 2015-12-16 | 2017-06-22 | Ecolab Usa Inc. | Peroxyformic acid compositions for membrane filtration cleaning |
UA127863C2 (uk) | 2015-12-16 | 2024-01-31 | Локсо Онколоджі, Інк. | Сполуки, які можна застосовувати як інгібітори кінази |
ES2854733T3 (es) | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
-
2016
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/en active Active
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/en active Application Filing
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 RS RS20201291A patent/RS60982B1/sr unknown
- 2016-12-16 CN CN202210312050.8A patent/CN114591242A/zh active Pending
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 CN CN202111022492.0A patent/CN113636978A/zh active Pending
- 2016-12-16 CN CN202210311995.8A patent/CN114634447A/zh active Pending
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active IP Right Grant
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 MX MX2018007267A patent/MX2018007267A/es unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/en active Active
- 2016-12-16 CN CN202111022488.4A patent/CN113603645A/zh active Pending
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 EP EP20194724.9A patent/EP3782994A1/en active Pending
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 MX MX2021003478A patent/MX2021003478A/es unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510A/zh active Pending
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 CN CN202210310724.0A patent/CN114716381A/zh active Pending
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko active Application Filing
- 2016-12-16 CN CN202210312064.XA patent/CN114605327A/zh active Pending
-
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
- 2018-11-06 HK HK18114157.0A patent/HK1263254A1/zh unknown
-
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-11-19 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
-
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
-
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
-
2023
- 2023-07-31 US US18/362,249 patent/US20230372298A1/en active Pending
-
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I1/fr active Active
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3390395T3 (da) | Forbindelser, der kan anvendes som kinase-inhibitorer | |
DK3303348T3 (da) | Naphthyridinforbindelser som JAK-kinaseinhibitorer | |
DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
DK3303334T3 (da) | Tyrosinkinasehæmmere | |
DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
DK3710446T3 (da) | Forbindelser, der kan anvendes til at hæmme CDK7 | |
DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
DK3461821T3 (da) | Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere | |
DK3190113T3 (da) | Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist | |
DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
DK3356345T3 (da) | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer | |
DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
DK3458460T3 (da) | Imidazoler som histondemethylase-inhibitorer | |
DK3288944T3 (da) | Imidazopyrazinoner som pde1-inhibitorer | |
DK3341379T3 (da) | EZH2-hæmmere | |
DK3552017T3 (da) | Forbindelser, der er anvendelige som ripk1-inhibitorer | |
DK3638680T3 (da) | Heteroaromatiske forbindelser som vanininhibitorer | |
DK3347360T3 (da) | Forbindelser, som er anvendelige til inhibering af ror-gamma-t | |
DK3497091T3 (da) | Kondenserede thiophen-derivater, der kan anvendes som NAPI-IIB-hæmmere |